Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2012 /
Next generation sequencing and WIN therapeutics

28th - 29th Jun 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.07.12
Views: 5114

Dr Michael Pellini – Foundation Medicine, Cambridge, USA

Dr Michael Pellini talks to ecancer at the 2012 WIN Symposium, Paris, about the investigation of next generation sequencing in the WINTHER project.


Dr Pellini and his company are researching targeted therapies and new testing methods, but he notes that these methods are part of a global effort to work through the challenges cancer presents.


Dr Pellini sees the WIN Consortium as a group of thought leaders attacking problems from a medical and global perspective. Foundation Medicine’s role in the WINTHER project, short for WIN Therapeutics, is comprehensively profiling each patient’s tumour.


Previously, molecular testing occurred with only a few biomarkers analysed. Next generation sequencing gives a much larger picture, but is very complex and expensive. Another aim of the study is to make this method practical and accessible in all clinical settings.


Filming supported by Amgen

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation